F. Eskens

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

F. Eskens, Constantijne H. Mom, André Planting et al. · British Journal of Cancer · 2007 · 230 citations · Full text

Influence of OATP1B1 Function on the Disposition of Sorafenib‐β‐D‐Glucuronide

Sander Bins, Leni van Doorn, AA Gibson et al. · Clinical and Translational Science · 2017 · 32 citations · Full text

Glycobiology, Immunology, Cholangiopathies +16

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. Puglisi, Leni van Doorn, Montserrat Blanco-Codesido et al. · Journal of Clinical Oncology · 2011 · 23 citations

Chemoprevention Strategy, Solid Tumors, Pharmacotherapy +16

An open-label phase I dose escalation study of KRN951, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 1 in a 4 week on, 2 week off schedule in patients with advanced solid tumors

F. Eskens, André Planting, Leni van Doorn et al. · Journal of Clinical Oncology · 2006 · 23 citations

Pathology, Pharmacotherapy, Metronomic Chemotherapy +20

A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently

Maja J.A. deJonge, S. Savage, Jaap Verweij et al. · Journal of Clinical Oncology · 2006 · 22 citations

Pharmaceutical Science, Erbb2 Tyrosine Kinases, Pathology +18